Pathophysiology of an origin of BPH - Course of hypotheses and theories, curent reality and perspectives


Authors: M. Fedorko
Published in: Urol List 2013; 11(2): 6-11

Overview

Benign prostatic hyperplasia is a condition characterized by prostate enlargment accompanied by lower urinary tract symptoms. Although the aetiopathogenesis is not yet fully understood, it is clear that several mechanisms, reviewed in the article, are involved in the development and progression of the disease. Pathophysiology of benign prostatic hyperplasia is complex. Effective treatment requires understanding of various factors causing lower urinary tract symptoms.

Key words:
benign prostatic hyperplasia, aetiology, pathophysiology


Sources

1. Jepsen JV, Bruskewitz RC. Clinical manifestation and indications for treatment. In: Lepor H. Prostatic Diseases. Philadelphia: WB Saunders 2000: 123–142.

2. Berry SJ, Coffey DS, Walsh PC et al. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132(3): 474–479.

3. Roehrborn CG et al. Benign Prostatic Hyperplasia: Etiology, Pathophysiology, Epidemiology and Natural History. Campbell-Walsh Urology, 10th edition. Philadelphia: Saunders 2012: 2570–2610.

4. Tag KY, Cho HJ. Benign Prostatic Hyperplasia: from bench to clonic. Korean J Urol 2012; 53(3): 139–148.

5. Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol 2005; 40(3): 121–128.

6. Loeb S, Kettermann A, Carter HB et al. Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging. J Urol 2009; 182(4): 1458–1462.

7. Briganti A, Capitano U, Suardi N et al. Benign Prostatic hyperplasia and its aetiologies. Eur Urol 2009; 8 (Suppl): 865–871.

8. Kyprianou N, Tu H, Jacobs SC. Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum Pathol 1996; 27(7): 668–675.

9. McConnell JD, 1995. Prostatic growth: new insights into hormonal regulation. Br J Urol 1995; 76 (Suppl 1): 5–10.

10. Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate 1984; 5(5): 545–557.

11. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate 1987; 2 (Suppl): 33–50.

12. McKeehan WL, Adams PS, Rozset MP. Direct mito­genic effects of insulin, epidermal growth factor, gluco­corticoid, cholera toxin, unknown pituitary factors and possibly prolactin, but not androgen, on normal rat prostate epithelial cells in serum-free, primary cell culture. Cancer Res 1984; 44(5): 1998–2010.

13. Thomas JA, Keenan EJ. Effects of estrogens on the prostate. J Androl 1994; 15(2): 97–99.

14. Smith P, Rhodes NP, Ke Y et al. Upregulation of estrogen and androgen receptors modulate expression of FGF-2 and FGF-7 in human, cultured, prostate stromal cells exposed to high concentrations of estradiol. Prostate Cancer Prostatic Dis 2002; 5(2): 105–110.

15. Lee KL, Peehl DM. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol 2004; 172(5 Pt 1): 1784–1791.

16. Grundy SM, Brewer HB Jr, Cleeman JI et al. Definition of Metabolic Syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004; 109: 433–438.

17. Hammarsten J, Högstedt B, Holthuis N et al. Components of the metabolit syndrome – risk factors for the development of benign prostatic hyperplasia. Prostate Cancor Prostatic Dis 1998; 1(3): 157–162.

18. Ozden C, Ozdal OL, Urgancioglu G et al. The cor­relation between metabolit syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 2007; 51(1): 199–203.

19. Boon TA, Van Venrooij GE, Eckhardt MD. Effect of diabetes mellitus on lower urinary tract ­symptoms and dysfunction in patients with benign prostatic hyperplasia. Curr Urol Rep 2001; 2(4): 297–301.

20. Nandeesha H. Benign prostatic hyperplasia: dietary and metabolit risk factors. Int Urol Nephrol 2008; 40(3): 649–656.

21. McVary KT, Rademaker A, Lloyd GL et al. Autonomic nervous system overactivity in men with lower urinary tract symtoms secondary to benign prostatic hyperplasia. J Urol 2005; 174(4 Pt 1): 1327–1433.

22. Kohnen PW, Drach GW. Patterns of inflamma­tion in prostatic hyperplasia: a histologic and bacterio­logic study. J Urol 1979; 121: 755–760.

23. Potts JM, Pasqualotto FF. Seminal oxidative stress in patients with chronic prostatitis. Andrologia 2003; 35: 304–308.

24. Sanda MG, Beaty TH et al. Genetic susceptibility of benign prostatic hyperplasia. J Urol 1994; 152(1): 115–119.

25. McNeal JE. Origin and evolution of benign prostatic enlargement. Invest Urol 1978; 15(4): 340–345.

26. Shapiro E, Becich MJ, Hartanto V et al. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol 1992; 147(5): 1293–1297.

27. Gup DI, Shapiro E, Baumann M et al. Contractile properties of human prostate adenomas and the development of infravesical obstruction. Prostate 1989; 15(2): 105–114.

28. Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med 1987; 317(10): 599–604.

29. Lepor H. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol 2004; 6 (Suppl 9): S3–S10.

30. Maruschke M, Protzel Ch, Hakenberg O. How to make a diagnosis of benign prostatic disease. Eur Urol 2009; 8 (6 Suppl): 490–495.

31. Elterman DS, Chughtai B, Lee RK et al. Update on phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Rev Urol 2012; ­14(3–4): 79–86.

32. Vyhnánková V, Pacík D. Tadalafil v léčbě LUTS/BPH a ED. Urol List 2013; 11(1): 11–14.

33. Morelli A, Chavalmane AK, Filippi S et al. Atorvastatin ameliorates sildenafil-induced penile erections in experimental diabetes by inhibiting diabetes-induced RhoA/Rho-kinase signaling hyperactivation. J Sex Med 2009; 6(1): 91–106.

34. Yassin A, Saad F, Hoesl CE et al. Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS-implications for clinical practice. Andrologia 2006; 38(1): 1–12.

35. Tarcan T, Azadzoi KM, Siroky MB et al. Age-related erectile and voiding dysfunction: the role of arterial insufficiency. Br J Urol 1998; 82 (Suppl 1): 26–33.

Labels
Paediatric urologist Urology
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account